Associate Professor Rachael Morton

Associate Professor
Director, Health Economics - NHMRC Clinical Trials Centre

Cancer research network

Telephone +61 2 9562 5013
Fax +61 2 9562 5387

Website Related website

Map

Biographical details

Rachael Morton is Associate Professor and Director of health economics at the NHMRC Clinical Trials Centre, Sydney Medical School, University of Sydney. She specialises in trial-based and modelled economic evaluation, and elicitation of patient preferences using discrete choice experiments. Her research incorporates patient-centred and economic outcomes into clinical trials of diagnostic tests, new treatments and models of care to facilitate policy decision-making on the basis of cost-effectiveness.

Research interests

A/Professor Morton’s research interests include the health economics of melanoma, and chronic kidney disease. She also has an interest in health equity in disadvantaged populations both in Australia and overseas. Her methodological interests include systematic reviews of economic evidence, assessment of test evaluation and monitoring, measurement of quality of life and wellbeing, and end-of-life care.

Teaching and supervision

A/Professor Morton is co-ordinator for two units of study in health economics within the Masters programmes in the Sydney Medical School / School of Public Health. These are: Making Decisions in Public Health (PUBH 5032) and Health Economics in Trials (CLTR 5006). She coordinates short courses in health economics for government and industry and currently supervises 5 PhD candidates.

Current projects

A/Professor Morton’s current melanoma projects include:

the cost-effectiveness of whole brain radiotherapy for brain metastases; the cost-effectiveness of pelvic lymph node surgery; the benefits and harms of CT and PET/CT surveillance in stage III melanoma; the cost-effectiveness of specialized surveillance in individuals at high risk of melanoma; the cost-effectiveness of presenting genomic risk information, and the safety and efficacy of high-dose Vitamin D to prevent melanoma recurrence. Many of these trials have been made possible through her longstanding collaboration with the Australia and New Zealand Melanoma Trials Group (ANZMTG), and the Melanoma Institute Australia.

A/Professor Morton’s current kidney projects include the cost-effectiveness of coronary artery disease screening in wait-listed recipients (CARSK trial); the impact of social determinants on kidney disease outcomes using data from the Study of Heart and Renal Protection (SHARP); a Cochrane review of interventions to aid employment for people on dialysis; and the evaluation of an advance care planning intervention for older patients managed with dialysis. Analysis of the SHARP trial data is a result of her overseas NHMRC fellowship and collaboration with the Health Economics Research Centre at the University of Oxford, UK in 2013-2015; as well as ongoing links with King’s College London.

The above studies are being undertaken with a range of collaborators at Sydney University, the Melanoma Institute Australia, the University of Ottawa & University of British Columbia, [Canada] and the University of Bristol, King’s College London & University of Oxford, [UK].

Associations

-Guest discussant, Economics Sub Committee of Pharmaceutical Benefits Advisory Committee, March 2013.

-Executive member, Dialysis Advisory Committee, Australia and New Zealand Society of Nephrology (ANZSN)

-Expert reference group – Joanna Briggs Institute

-Member, Cochrane Equity Methods Group

-Member, International Health Economics Association

Awards and honours

2016 - Honorary Investigator, Melanoma Institute Australia

2015 - Helen Triantyfallou Conference award, (Top ranked applicant) Sydney Medical School, University of Sydney

2010 - Dean’s prize for Student Research publications, Commendation, Sydney Medical School, University of Sydney

International grants:

Dunhill Medical Trust (UK). “Advance care planning with older patients who have end-stage kidney disease: Feasibility of a deferred entry randomised controlled trial incorporating a mixed methods process evaluation.” CIs O’Halloran P, Brazil K, Noble H, Fogarty D, Murtagh F, Brown J, Shields J, Morton RL.

European Centre for Disease Control, European Union (EU). “Effectiveness and cost-effectiveness of screening migrants in Europe.” Pottie K, Vandvik P, Morton RL.

New Zealand Heart Foundation. “Canadian-Australasian Randomised trialof Screening Kidney transplant recipients for coronary artery disease (CARSK study).” Pilmore H, Chadban S, Cross N, Morton RL.

Other national grants:

Australian Government – Department of Health. National Palliative Care Projects.“Supporting provision of palliative care and advance care planning in general practice: a toolkit and training package targeting practice nurses.” Clayton J, Tieman J, Sylvester W, Halcomb E, Mitchell G, Phillips J, Shaw T, Morton RL.

International links

Canada

(Bruyere Institute, University of Ottawa ) Since 2013 I have been working with the Cochrane Equity [and Economics] Methods groups to look at ways of combining evidence into systematic reviews using the GRADE methodology

Canada

(Vancouver hospital, University of British Columbia) I am collaborating with nephrologists, health economists and biostatisticians to examine multi-country cost-effectiveness of screening kidney transplant recipients for heart disease.

United Kingdom

(Cicely Saunders Institute, King┬┐s College London ) Since 2012 I have worked with palliative care physicians to assess resource use, costs and quality of life in end-of-life care for people with kidney disease.

United Kingdom

(Health Economics Research Centre, University of Oxford) Since 2012 I have been part of a multi-disciplinary team of health economists, epidemiologists and clinicians to assess the impact of social determinants of health (such as educational attainment and household income) on cardiovascular and kidney outcomes.

Selected grants

2015

  • Translating our knowledge of genomics to improve skin cancer prevention: a pilot randomized controlled trial to evaluate whether knowledge of personal genetic risk of melanoma motivates behaviour change; Cust A, Newson A, Kimlin M, Kirk J, Keogh L, Law M, Morton R, Williams G, Butow P, Dobbinson S; DVC Research/SPARC Implementation - Cancer.

2014

  • Evaluation of Groin Lymphandenectomy Extent for metastatic Melanoma (Inguinal or Ilio-inguinal Lymphandenectomy for metastatic melanoma to groin lymph nodes and no pelvic disease on PET/CT Scan - a randomised controlled trial); ANZMTG 01.12 EAGLE FM Study; Spillane A, Henderson M, King M, Morton R, Henderson M, Allan C; Cancer Council New South Wales/Research Project Grants.
  • Investigating barriers and facilitators to advance care planning for dialysis and pre-dialysis patients; Clayton J, Pollock C, Luckett T, Morton R, Silvester W, Detering K, Spencer L; Kidney Health Australia/Research Support.

2013

  • Analysis of socio-economic status on cholesterol lowering interventions in chronic kidney disease; Morton R; National Health and Medical Research Council (NHMRC)/Early Career Fellowships.
  • The cost-effectiveness of adjuvant whole brain radiotherapy for melanoma brain metastases: a trial-based and modeled economic evaluation; Morton R, King M, Fogarty G, Nowak A, Hong A; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2012

  • Patient INformation about Options for Treatments (PINOT): A prospective observational cohort study, five year follow-up.; Morton R; Kidney Health Australia/Project Grant.

2006

  • Strengthen Cancer Care initiative - Infrastructure Support for Clinical Trials Program; Thompson J, Morton R; Cancer Australia/Support for Cancer Clinical Trials - Existing National Cooperative Oncology groups.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Morton, R., Webster, A. (2014). Quality of Life in Chronic Kidney Disease. In Mustafa Arici (Eds.), Management of Chronic Kidney Disease, (pp. 487-499). Berlin: Springer-Verlag.

Journals

  • Morton, R., Schlackow, I., Staplin, N., Gray, A., Cass, A., Haynes, R., Emberson, J., Herrington, W., Landray, M., Baigent, C., et al (2016). Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. American Journal of Kidney Diseases, 67(1), 31-39. [More Information]
  • Wyld, M., Chadban, S., Morton, R. (2016). Improving Our Understanding of Quality of Life in CKD. American Journal of Kidney Diseases, 67(6), 820-821. [More Information]
  • Walker, R., Howard, K., Morton, R., Palmer, S., Marshall, M., Tong, A. (2016). Patient and caregiver values, beliefs and experiences when considering home dialysis as a treatment option: a semi-structured interview study. Nephrology, Dialysis, Transplantation, 31(1), 133-141. [More Information]
  • Morton, R., Schlackow, I., Mihaylova, B., Staplin, N., Gray, A., Cass, A. (2016). The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review. Nephrology, Dialysis, Transplantation, 31(1), 46-56. [More Information]
  • Watts, C., Dieng, M., Morton, R., Mann, G., Menzies, S., Cust, A. (2015). Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review. British Journal of Dermatology, 172(1), 33-47. [More Information]
  • Wyld, M., Lee, C., Zhou, X., White, S., Shaw, J., Morton, R., Colagiuri, S., Chadban, S. (2015). Cost to Government and Society of Chronic Kidney Disease Stage 1-5, a National Cohort Study. Internal Medicine Journal, 45(7), 741-747. [More Information]
  • Davison, S., Levin, A., Moss, A., Jha, V., Brown, E., Brennan, F., Murtagh, F., Naicker, S., Germain, M., O'Donoughe, D., Morton, R., et al (2015). Executive summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: developing a roadmap to improving quality care. Kidney International, 88(3), 447-459. [More Information]
  • Howard, K., McFarlane, P., Marshall, M., Eastwood, D., Morton, R. (2015). Funding and planning: What you need to know for starting or expanding a home hemodialysis program. Hemodialysis International, 19(Suppl 1), S23-42. [More Information]
  • Memari, N., Hayen, A., Bell, K., Rychetnik, L., Morton, R., McCaffery, K., Thompson, J., Irwig, L., Turner, R. (2015). How Often Do Patients with Localized Melanoma Attend Follow-Up at a Specialist Center? Annals of Surgical Oncology, 22(Supp 3), 1164-1171. [More Information]
  • Breckenridge, K., Bekker, H., Gibbons, E., van der Veer, S., Abbott, D., Briancon, S., Cullen, R., Graneata, L., Jager, K., Lonning, K., Morton, R., et al (2015). How to routinely collect data on patient-reported outcome and experience measures in renal registries in Europe: an expert consensus meeting. Nephrology, Dialysis, Transplantation, 30(10), 1605-1614. [More Information]
  • Walker, R., Hanson, C., Palmer, S., Howard, K., Morton, R., Marshall, M., Tong, A. (2015). Patient and Caregiver Perspectives on Home Hemodialysis: A Systematic Review. American Journal of Kidney Diseases, 65(3), 451-463. [More Information]
  • Walker, R., Morton, R., Tong, A., Marshall, M., Palmer, S., Howard, K. (2015). Patient and caregiver preferences for home dialysis-The home first study: A protocol for qualitative interviews and discrete choice experiments. BMJ Open, 5(4), 1-6. [More Information]
  • Watts, C., Cust, A., Menzies, S., Coates, E., Mann, G., Morton, R. (2015). Specialized surveillance for individuals at high risk for melanoma a cost analysis of a high-risk clinic. JAMA Dermatology, 151(2), 178-186. [More Information]
  • Dieng, M., Kasparian, N., Morton, R., Mann, G., Butow, P., Menzies, S., Costa, D., Cust, A. (2015). The Melanoma care study: protocol of a randomised controlled trial of a psycho-educational intervention for melanoma survivors at high risk of developing new primary disease. BMC Psychology, 3(1), 1-13. [More Information]
  • Saw, R., Armstrong, B., Mason, R., Morton, R., Shannon, K., Spillane, A., Stretch, J., Thompson, J. (2014). Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D). BMC Cancer, 14, 1-10. [More Information]
  • Foote, C., Morton, R., Jardine, M., Gallagher, M., Brown, M., Howard, K., Cass, A. (2014). Considerations of Nephrologists when SuggestIng Dialysis in Elderly patients with Renal failure (CONSIDER): a discrete choice experiment. Nephrology, Dialysis, Transplantation, 29(12), 2302-2309. [More Information]
  • Morton, R. (2014). Essential inputs for studies of cost-effectiveness analysis in melanoma. British Journal of Dermatology, 171(6), 1294-1295. [More Information]
  • Wong, G., Howard, K., Webster, A., Morton, R., Chapman, J., Craig, J. (2014). How is health economics relevant to transplant clinicians? Transplantation, 98(2), 124-130. [More Information]
  • Asha, S., Chan, A., Walter, E., Kelly, P., Morton, R., Ajami, A., Wilson, R., Honneyman, D. (2014). Impact from point-of-care devices on emergency department patient processing times compared with central laboratory testing of blood samples: a randomised controlled trial and cost-effectiveness analysis. Emergency Medicine Journal, 31(9), 714-719. [More Information]
  • Dieng, M., Watts, C., Kasparian, N., Morton, R., Mann, G., Cust, A. (2014). Improving subjective perception of personal cancer risk: systematic review and meta-analysis of educational interventions for people with cancer or at high risk of cancer. Psycho-Oncology, 23(6), 613-625. [More Information]
  • Fortnum, D., Ludlow, M., Morton, R. (2014). Renal unit characteristics and patient education practices that predict a high prevalence of home-based dialysis in Australia. Nephrology, 19(9), 587-593. [More Information]
  • Walker, R., Marshall, M., Morton, R., McFarlane, P., Howard, K. (2014). The cost effectiveness of contemporary home haemodialysis modalities compared to facility haemodialysis: A systematic review of full economic evaluations. Nephrology, 19(8), 459-470. [More Information]
  • Wyld, M., Clayton, P., Morton, R., Chadban, S. (2013). Anti-Coagulation, anti-platelets or no therapy in haemodialysis patients with atrial fibrillation: A decision analysis. Nephrology, 18(12), 783-789. [More Information]
  • Walker, R., Fassett, R., Morton, R. (2013). ANZSN renal supportive care guidelines 2013: Research Issues in elderly patients: gaps in knowledge and suggested directions. Nephrology, 18(6), 439-441.
  • Merom, D., Cumming, R., Mathieu, E., Anstey, K., Rissel, C., Simpson, J., Morton, R., Cerin, E., Sherrington, C., Lord, S. (2013). Can social dancing prevent falls in older adults? a protocol of the Dance, Aging, Cognition, Economics (DAnCE) fall prevention randomised controlled trial. BMC Public Health, 13(1), 1-9. [More Information]
  • Rychetnik, L., McCaffery, K., Morton, R., Thompson, J., Menzies, S., Irwig, L. (2013). Follow-Up of Early Stage Melanoma: Specialist Clinician Perspectives on the Functions of Follow-Up and Implications for Extending Follow-Up Intervals. Journal of Surgical Oncology, 107(5), 463-468. [More Information]
  • Morton, R., Rychetnik, L., McCaffery, K., Thompson, J., Irwig, L. (2013). Patients' perspectives of long-term follow-up for localised cutaneous melanoma. European Journal of Surgical Oncology, 39, 297-303. [More Information]
  • Rychetnik, L., McCaffery, K., Morton, R., Irwig, L. (2013). Psychosocial aspects of post-treatment follow-up for stage I/II melanoma: a systematic review of the literature. Psycho-Oncology, 22(4), 721-736. [More Information]
  • Wyld, M., Morton, R., Hayen, A., Howard, K., Webster, A. (2012). A Systematic Review and Meta-Analysis of Utility-Based Quality of Life in Chronic Kidney Disease Treatments. PLoS Medicine, 9(9), 1-10. [More Information]
  • Morton, R., Snelling, P., Webster, A., Rose, J., Masterson, R., Johnson, D., Howard, K. (2012). Dialysis Modality Preference of Patients With CKD and Family Caregivers: A Discrete-Choice Study. American Journal of Kidney Diseases, 60(1), 102-111. [More Information]
  • Morton, R., Snelling, P., Webster, A., Rose, J., Masterson, R., Johnson, D., Howard, K. (2012). Factors influencing patient choice of dialysis versus conservative care to treat end-stage kidney disease. CMAJ, 184(5), E277-E283. [More Information]
  • Morton, R., Turner, R., Howard, K., Snelling, P., Webster, A. (2012). Patients Who Plan for Conservative Care Rather Than Dialysis: A National Observational Study in Australia. American Journal of Kidney Diseases, 59(3), 419-427. [More Information]
  • Rychetnik, L., Morton, R., McCaffery, K., Thompson, J., Menzies, S., Irwig, L. (2012). Shared care in the follow-up of early-stage melanoma: a qualitative study of Australian melanoma clinicians' perspectives and models of care. BMC Health Services Research, 12, 1-9. [More Information]
  • Tong, A., Morton, R., Howard, K., McTaggart, S., Craig, J. (2011). "When I had my transplant, I became normal." Adolescent perspectives on life after kidney transplantation. Pediatric Transplantation, 15(3), 285-293. [More Information]
  • Morton, R., Tong, A., Webster, A., Snelling, P., Howard, K. (2011). Characteristics of dialysis important to patients and family caregivers: a mixed methods approach. Nephrology, Dialysis, Transplantation, 26(12), 4038-4046. [More Information]
  • Turner, R., Bell, K., Morton, R., Hayen, A., Francken, A., Howard, K., Armstrong, B., Thompson, J., Irwig, L. (2011). Optimizing the Frequency of Follow-Up Visits for Patients Treated for Localized Primary Cutaneous Melanoma. Journal of Clinical Oncology, 29(35), 4641-4646. [More Information]
  • Tong, A., Tjaden, L., Howard, K., Wong, G., Morton, R., Craig, J. (2011). Quality of Life of Adolescent Kidney Transplant Recipients. The Journal of Pediatrics, 159(4), 670-675. [More Information]
  • Fogarty, G., Morton, R., Vardy, J., Nowak, A., Mandel, C., Forder, P., Hong, A., Hruby, G., Burmeister, B., Shivalingam, B., Dhillon, H., Thompson, J. (2011). Whole brain radiotherapy after local treatment of brain metastases in melanoma patients - a randomised phase III trial. BMC Cancer, 11(142), 1-8. [More Information]
  • Tong, A., Morton, R., Howard, K., McTaggart, S., Craig, J. (2010). 'When I had my transplant, I became normal.' adolescent perspectives on life after kidney transplantation. Nephrology, 15(S4), 64-64. [More Information]
  • Morton, R., Howard, K., Thompson, J. (2010). In Reply: Cost Effectiveness of Staging Procedures in Patients with Stage I/II Melanoma. Annals of Surgical Oncology, 17(2), 663-664. [More Information]
  • Morton, R., Howard, K., Webster, A., Snelling, P. (2010). Patient INformation about Options for Treatment (PINOT): a prospective national study of information given to incident CKD Stage 5 patients. Nephrology, Dialysis, Transplantation, doi: 10.1093/ndt/gfq555(unspecified), 1-9. [More Information]
  • Morton, R., Howard, K., Webster, A., Snelling, P. (2010). Patient information about options for treatment: Methods of a national audit of information provision in chronic kidney disease. Nephrology, 15(6), 649-652. [More Information]
  • Morton, R., Devitt, J., Howard, K., Anderson, K., Snelling, P., Cass, A. (2010). Patient views about treatment of stage 5 CKD: a qualitative analysis of semistructured interviews. American Journal of Kidney Diseases, 55(3), 431-440. [More Information]
  • Morton, R., Tong, A., Howard, K., Snelling, P., Webster, A. (2010). The views of patients and carers in treatment decision making for chronic kidney disease: a systematic review of qualitative studies. BMJ, 340(7742), 1-10. [More Information]
  • Morton, R., Moustakas, J., Howard, K., Webster, A., Snelling, P. (2009). A national audit of information provided to new chronic kidney disease stage 4 & 5 patients: results from a pilot study. Renal Society of Australasia Journal, 5(3), 138-146.
  • Tong, A., Morton, R., Howard, K., Craig, J. (2009). Adolescent Experiences Following Organ Transplantation: A Systematic Review of Qualitative Studies. The Journal of Pediatrics, 155(4), 542-549. [More Information]
  • Thompson, J., Morton, R. (2009). In Reply: Cost-Effectiveness of Sentinel Node Biopsy for Melanoma. Annals of Surgical Oncology, 16(10), 2962-2963. [More Information]
  • Morton, R., Howard, K., Webster, A., Wong, G., Craig, J. (2009). The cost-effectiveness of induction immunosuppression in kidney transplantation. Nephrology, Dialysis, Transplantation, 24(7), 2258-2269. [More Information]
  • Morton, R., Craig, J., Thompson, J. (2009). The Role of Surveillance Chest X-Rays in the Follow-Up of High-Risk Melanoma Patients. Annals of Surgical Oncology, 16(3), 571-577. [More Information]
  • Morton, R., Howard, K., Thompson, J. (2008). The Cost-Effectiveness of Sentinel Node Biopsy in Patients with Intermediate Thickness Primary Cutaneous Melanoma. Annals of Surgical Oncology, 16(4), 929-940. [More Information]
  • Uren, R., Howman-Giles, R., Chung, D., Morton, R., Thompson, J. (2006). The Reproducibility in Routine Clinical Practice of Sentinel Lymph Node Identification by Pre-operative Lymphoscintigraphy in Patients with Cutaneous Melanoma. Annals of Surgical Oncology, 14(2), 899-905. [More Information]

Conferences

  • Tong, A., Tjaden, L., Howard, K., Wong, G., Morton, R., Craig, J. (2011). Quality of Life of Adolescent Kidney Transplant Recipients. 2011 Transplantation Society of Australia and New Zealand (TSANZ), 29th Annual Scientific Meeting, Canberra, Australia.

2016

  • Morton, R., Schlackow, I., Staplin, N., Gray, A., Cass, A., Haynes, R., Emberson, J., Herrington, W., Landray, M., Baigent, C., et al (2016). Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. American Journal of Kidney Diseases, 67(1), 31-39. [More Information]
  • Wyld, M., Chadban, S., Morton, R. (2016). Improving Our Understanding of Quality of Life in CKD. American Journal of Kidney Diseases, 67(6), 820-821. [More Information]
  • Walker, R., Howard, K., Morton, R., Palmer, S., Marshall, M., Tong, A. (2016). Patient and caregiver values, beliefs and experiences when considering home dialysis as a treatment option: a semi-structured interview study. Nephrology, Dialysis, Transplantation, 31(1), 133-141. [More Information]
  • Morton, R., Schlackow, I., Mihaylova, B., Staplin, N., Gray, A., Cass, A. (2016). The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review. Nephrology, Dialysis, Transplantation, 31(1), 46-56. [More Information]

2015

  • Watts, C., Dieng, M., Morton, R., Mann, G., Menzies, S., Cust, A. (2015). Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review. British Journal of Dermatology, 172(1), 33-47. [More Information]
  • Wyld, M., Lee, C., Zhou, X., White, S., Shaw, J., Morton, R., Colagiuri, S., Chadban, S. (2015). Cost to Government and Society of Chronic Kidney Disease Stage 1-5, a National Cohort Study. Internal Medicine Journal, 45(7), 741-747. [More Information]
  • Davison, S., Levin, A., Moss, A., Jha, V., Brown, E., Brennan, F., Murtagh, F., Naicker, S., Germain, M., O'Donoughe, D., Morton, R., et al (2015). Executive summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: developing a roadmap to improving quality care. Kidney International, 88(3), 447-459. [More Information]
  • Howard, K., McFarlane, P., Marshall, M., Eastwood, D., Morton, R. (2015). Funding and planning: What you need to know for starting or expanding a home hemodialysis program. Hemodialysis International, 19(Suppl 1), S23-42. [More Information]
  • Memari, N., Hayen, A., Bell, K., Rychetnik, L., Morton, R., McCaffery, K., Thompson, J., Irwig, L., Turner, R. (2015). How Often Do Patients with Localized Melanoma Attend Follow-Up at a Specialist Center? Annals of Surgical Oncology, 22(Supp 3), 1164-1171. [More Information]
  • Breckenridge, K., Bekker, H., Gibbons, E., van der Veer, S., Abbott, D., Briancon, S., Cullen, R., Graneata, L., Jager, K., Lonning, K., Morton, R., et al (2015). How to routinely collect data on patient-reported outcome and experience measures in renal registries in Europe: an expert consensus meeting. Nephrology, Dialysis, Transplantation, 30(10), 1605-1614. [More Information]
  • Walker, R., Hanson, C., Palmer, S., Howard, K., Morton, R., Marshall, M., Tong, A. (2015). Patient and Caregiver Perspectives on Home Hemodialysis: A Systematic Review. American Journal of Kidney Diseases, 65(3), 451-463. [More Information]
  • Walker, R., Morton, R., Tong, A., Marshall, M., Palmer, S., Howard, K. (2015). Patient and caregiver preferences for home dialysis-The home first study: A protocol for qualitative interviews and discrete choice experiments. BMJ Open, 5(4), 1-6. [More Information]
  • Watts, C., Cust, A., Menzies, S., Coates, E., Mann, G., Morton, R. (2015). Specialized surveillance for individuals at high risk for melanoma a cost analysis of a high-risk clinic. JAMA Dermatology, 151(2), 178-186. [More Information]
  • Dieng, M., Kasparian, N., Morton, R., Mann, G., Butow, P., Menzies, S., Costa, D., Cust, A. (2015). The Melanoma care study: protocol of a randomised controlled trial of a psycho-educational intervention for melanoma survivors at high risk of developing new primary disease. BMC Psychology, 3(1), 1-13. [More Information]

2014

  • Saw, R., Armstrong, B., Mason, R., Morton, R., Shannon, K., Spillane, A., Stretch, J., Thompson, J. (2014). Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D). BMC Cancer, 14, 1-10. [More Information]
  • Foote, C., Morton, R., Jardine, M., Gallagher, M., Brown, M., Howard, K., Cass, A. (2014). Considerations of Nephrologists when SuggestIng Dialysis in Elderly patients with Renal failure (CONSIDER): a discrete choice experiment. Nephrology, Dialysis, Transplantation, 29(12), 2302-2309. [More Information]
  • Morton, R. (2014). Essential inputs for studies of cost-effectiveness analysis in melanoma. British Journal of Dermatology, 171(6), 1294-1295. [More Information]
  • Wong, G., Howard, K., Webster, A., Morton, R., Chapman, J., Craig, J. (2014). How is health economics relevant to transplant clinicians? Transplantation, 98(2), 124-130. [More Information]
  • Asha, S., Chan, A., Walter, E., Kelly, P., Morton, R., Ajami, A., Wilson, R., Honneyman, D. (2014). Impact from point-of-care devices on emergency department patient processing times compared with central laboratory testing of blood samples: a randomised controlled trial and cost-effectiveness analysis. Emergency Medicine Journal, 31(9), 714-719. [More Information]
  • Dieng, M., Watts, C., Kasparian, N., Morton, R., Mann, G., Cust, A. (2014). Improving subjective perception of personal cancer risk: systematic review and meta-analysis of educational interventions for people with cancer or at high risk of cancer. Psycho-Oncology, 23(6), 613-625. [More Information]
  • Morton, R., Webster, A. (2014). Quality of Life in Chronic Kidney Disease. In Mustafa Arici (Eds.), Management of Chronic Kidney Disease, (pp. 487-499). Berlin: Springer-Verlag.
  • Fortnum, D., Ludlow, M., Morton, R. (2014). Renal unit characteristics and patient education practices that predict a high prevalence of home-based dialysis in Australia. Nephrology, 19(9), 587-593. [More Information]
  • Walker, R., Marshall, M., Morton, R., McFarlane, P., Howard, K. (2014). The cost effectiveness of contemporary home haemodialysis modalities compared to facility haemodialysis: A systematic review of full economic evaluations. Nephrology, 19(8), 459-470. [More Information]

2013

  • Wyld, M., Clayton, P., Morton, R., Chadban, S. (2013). Anti-Coagulation, anti-platelets or no therapy in haemodialysis patients with atrial fibrillation: A decision analysis. Nephrology, 18(12), 783-789. [More Information]
  • Walker, R., Fassett, R., Morton, R. (2013). ANZSN renal supportive care guidelines 2013: Research Issues in elderly patients: gaps in knowledge and suggested directions. Nephrology, 18(6), 439-441.
  • Merom, D., Cumming, R., Mathieu, E., Anstey, K., Rissel, C., Simpson, J., Morton, R., Cerin, E., Sherrington, C., Lord, S. (2013). Can social dancing prevent falls in older adults? a protocol of the Dance, Aging, Cognition, Economics (DAnCE) fall prevention randomised controlled trial. BMC Public Health, 13(1), 1-9. [More Information]
  • Rychetnik, L., McCaffery, K., Morton, R., Thompson, J., Menzies, S., Irwig, L. (2013). Follow-Up of Early Stage Melanoma: Specialist Clinician Perspectives on the Functions of Follow-Up and Implications for Extending Follow-Up Intervals. Journal of Surgical Oncology, 107(5), 463-468. [More Information]
  • Morton, R., Rychetnik, L., McCaffery, K., Thompson, J., Irwig, L. (2013). Patients' perspectives of long-term follow-up for localised cutaneous melanoma. European Journal of Surgical Oncology, 39, 297-303. [More Information]
  • Rychetnik, L., McCaffery, K., Morton, R., Irwig, L. (2013). Psychosocial aspects of post-treatment follow-up for stage I/II melanoma: a systematic review of the literature. Psycho-Oncology, 22(4), 721-736. [More Information]

2012

  • Wyld, M., Morton, R., Hayen, A., Howard, K., Webster, A. (2012). A Systematic Review and Meta-Analysis of Utility-Based Quality of Life in Chronic Kidney Disease Treatments. PLoS Medicine, 9(9), 1-10. [More Information]
  • Morton, R., Snelling, P., Webster, A., Rose, J., Masterson, R., Johnson, D., Howard, K. (2012). Dialysis Modality Preference of Patients With CKD and Family Caregivers: A Discrete-Choice Study. American Journal of Kidney Diseases, 60(1), 102-111. [More Information]
  • Morton, R., Snelling, P., Webster, A., Rose, J., Masterson, R., Johnson, D., Howard, K. (2012). Factors influencing patient choice of dialysis versus conservative care to treat end-stage kidney disease. CMAJ, 184(5), E277-E283. [More Information]
  • Morton, R., Turner, R., Howard, K., Snelling, P., Webster, A. (2012). Patients Who Plan for Conservative Care Rather Than Dialysis: A National Observational Study in Australia. American Journal of Kidney Diseases, 59(3), 419-427. [More Information]
  • Rychetnik, L., Morton, R., McCaffery, K., Thompson, J., Menzies, S., Irwig, L. (2012). Shared care in the follow-up of early-stage melanoma: a qualitative study of Australian melanoma clinicians' perspectives and models of care. BMC Health Services Research, 12, 1-9. [More Information]

2011

  • Tong, A., Morton, R., Howard, K., McTaggart, S., Craig, J. (2011). "When I had my transplant, I became normal." Adolescent perspectives on life after kidney transplantation. Pediatric Transplantation, 15(3), 285-293. [More Information]
  • Morton, R., Tong, A., Webster, A., Snelling, P., Howard, K. (2011). Characteristics of dialysis important to patients and family caregivers: a mixed methods approach. Nephrology, Dialysis, Transplantation, 26(12), 4038-4046. [More Information]
  • Turner, R., Bell, K., Morton, R., Hayen, A., Francken, A., Howard, K., Armstrong, B., Thompson, J., Irwig, L. (2011). Optimizing the Frequency of Follow-Up Visits for Patients Treated for Localized Primary Cutaneous Melanoma. Journal of Clinical Oncology, 29(35), 4641-4646. [More Information]
  • Tong, A., Tjaden, L., Howard, K., Wong, G., Morton, R., Craig, J. (2011). Quality of Life of Adolescent Kidney Transplant Recipients. The Journal of Pediatrics, 159(4), 670-675. [More Information]
  • Tong, A., Tjaden, L., Howard, K., Wong, G., Morton, R., Craig, J. (2011). Quality of Life of Adolescent Kidney Transplant Recipients. 2011 Transplantation Society of Australia and New Zealand (TSANZ), 29th Annual Scientific Meeting, Canberra, Australia.
  • Fogarty, G., Morton, R., Vardy, J., Nowak, A., Mandel, C., Forder, P., Hong, A., Hruby, G., Burmeister, B., Shivalingam, B., Dhillon, H., Thompson, J. (2011). Whole brain radiotherapy after local treatment of brain metastases in melanoma patients - a randomised phase III trial. BMC Cancer, 11(142), 1-8. [More Information]

2010

  • Tong, A., Morton, R., Howard, K., McTaggart, S., Craig, J. (2010). 'When I had my transplant, I became normal.' adolescent perspectives on life after kidney transplantation. Nephrology, 15(S4), 64-64. [More Information]
  • Morton, R., Howard, K., Thompson, J. (2010). In Reply: Cost Effectiveness of Staging Procedures in Patients with Stage I/II Melanoma. Annals of Surgical Oncology, 17(2), 663-664. [More Information]
  • Morton, R., Howard, K., Webster, A., Snelling, P. (2010). Patient INformation about Options for Treatment (PINOT): a prospective national study of information given to incident CKD Stage 5 patients. Nephrology, Dialysis, Transplantation, doi: 10.1093/ndt/gfq555(unspecified), 1-9. [More Information]
  • Morton, R., Howard, K., Webster, A., Snelling, P. (2010). Patient information about options for treatment: Methods of a national audit of information provision in chronic kidney disease. Nephrology, 15(6), 649-652. [More Information]
  • Morton, R., Devitt, J., Howard, K., Anderson, K., Snelling, P., Cass, A. (2010). Patient views about treatment of stage 5 CKD: a qualitative analysis of semistructured interviews. American Journal of Kidney Diseases, 55(3), 431-440. [More Information]
  • Morton, R., Tong, A., Howard, K., Snelling, P., Webster, A. (2010). The views of patients and carers in treatment decision making for chronic kidney disease: a systematic review of qualitative studies. BMJ, 340(7742), 1-10. [More Information]

2009

  • Morton, R., Moustakas, J., Howard, K., Webster, A., Snelling, P. (2009). A national audit of information provided to new chronic kidney disease stage 4 & 5 patients: results from a pilot study. Renal Society of Australasia Journal, 5(3), 138-146.
  • Tong, A., Morton, R., Howard, K., Craig, J. (2009). Adolescent Experiences Following Organ Transplantation: A Systematic Review of Qualitative Studies. The Journal of Pediatrics, 155(4), 542-549. [More Information]
  • Thompson, J., Morton, R. (2009). In Reply: Cost-Effectiveness of Sentinel Node Biopsy for Melanoma. Annals of Surgical Oncology, 16(10), 2962-2963. [More Information]
  • Morton, R., Howard, K., Webster, A., Wong, G., Craig, J. (2009). The cost-effectiveness of induction immunosuppression in kidney transplantation. Nephrology, Dialysis, Transplantation, 24(7), 2258-2269. [More Information]
  • Morton, R., Craig, J., Thompson, J. (2009). The Role of Surveillance Chest X-Rays in the Follow-Up of High-Risk Melanoma Patients. Annals of Surgical Oncology, 16(3), 571-577. [More Information]

2008

  • Morton, R., Howard, K., Thompson, J. (2008). The Cost-Effectiveness of Sentinel Node Biopsy in Patients with Intermediate Thickness Primary Cutaneous Melanoma. Annals of Surgical Oncology, 16(4), 929-940. [More Information]

2006

  • Uren, R., Howman-Giles, R., Chung, D., Morton, R., Thompson, J. (2006). The Reproducibility in Routine Clinical Practice of Sentinel Lymph Node Identification by Pre-operative Lymphoscintigraphy in Patients with Cutaneous Melanoma. Annals of Surgical Oncology, 14(2), 899-905. [More Information]

To update your profile click here. For support on your academic profile contact .